TransMolecular Successfully Completes Phase I/II Clinical Trial With its Targeted Oncology Therapeutic
09-Dec-2004 -
TransMolecular, Inc. announced that based on the favorable initial safety and tolerability profile
of its anti-cancer therapeutic, 131I-TM-601 for recurrent glioma or metastatic
brain cancer, it is initiating a Phase II multi-center North American clinical
trial to include 66 patients with adult ...
amino acids
brain cancer
brain tumors
+11